Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The CMML Channel

Explore the latest updates and expert interviews

Welcome to The Chronic Myelomonocytic Leukemia (CMML) Channel

Reporting from key international congresses and speaking with world-leading experts, VJHemOnc’s CMML Channel delivers video interviews on the prognostication, treatment, and management of CMML.

Molecular biology and clinical outcomes of blast-transformed CMML 17:19
Molecular biology and clinical outcomes of blast-transformed CMML
Mrinal Patnaik • 19 Sep 2026
Updates on targeting PI3 kinase gamma in myeloid malignancies 12:56
Updates on targeting PI3 kinase gamma in myeloid malignancies
Andrew Lane • 18 Sep 2026
Understanding the biology and therapeutic potential of RAS in frontline AML and CMML 9:57
Understanding the biology and therapeutic potential of RAS in frontline AML and CMML
Sandra Misale • 18 Sep 2026
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs? 2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting 36:15
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
Amer Zeidan et al. • 19 Mar 2026
Investigating PTCy with uhCG/EGF as GvHD prophylaxis for mismatched unrelated donor transplantation 2:33
Investigating PTCy with uhCG/EGF as GvHD prophylaxis for mismatched unrelated donor transplantation
Shatha Farhan • 17 Feb 2026
The potential of using CXCL9 as a prognostic indicator following alloSCT 1:36
The potential of using CXCL9 as a prognostic indicator following alloSCT
Shatha Farhan • 17 Feb 2026
Early recognition and diagnosis of BPDCN: skin biopsy, markers, and specialist referral 1:03
Early recognition and diagnosis of BPDCN: skin biopsy, markers, and specialist referral
Andrew Lane • 6 Dec 2025
Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic CMML 1:35
Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic CMML
Sanam Loghavi • 6 Dec 2025
Oral decitabine-cedazuridine in combination with venetoclax in treatment-naïve HR-MDS or CMML 1:19
Oral decitabine-cedazuridine in combination with venetoclax in treatment-naïve HR-MDS or CMML
Alex Bataller • 8 Dec 2025
The global ABNL-MARRO trials and revised response criteria for MDS/MPN overlap syndromes 1:24
The global ABNL-MARRO trials and revised response criteria for MDS/MPN overlap syndromes
Michael Savona • 6 Dec 2025
An upcoming Phase II trial of eltrombopag in low-risk MDS and CMML harboring TET2 mutations 1:54
An upcoming Phase II trial of eltrombopag in low-risk MDS and CMML harboring TET2 mutations
Abhay Singh • 6 Dec 2025
TAG-AZA-VEN triplet therapy in patients with BPDCN: results of a Phase II trial 2:26
TAG-AZA-VEN triplet therapy in patients with BPDCN: results of a Phase II trial
Andrew Lane • 6 Dec 2025
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes 4:47
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes
Daniel Wiseman • 6 Dec 2025
Multimodal assessment of CMML with extramedullary involvement reveals RAS pathway activation 2:21
Multimodal assessment of CMML with extramedullary involvement reveals RAS pathway activation
Sanam Loghavi • 6 Dec 2025
Lessons learned from recently failed Phase III clinical trials in HR-MDS 1:50
Lessons learned from recently failed Phase III clinical trials in HR-MDS
Maximilian Stahl • 5 Dec 2025

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals